FDA Approves Abrocitinib for Adolescents With Atopic Dermatitis FDA Approves Abrocitinib for Adolescents With Atopic Dermatitis

The approval means that adolescents aged 12 to 17 with refractory, moderate to severe AD have a new systemic once-daily oral option.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Alert Source Type: news